Select a medication above to begin.
Mydayis
dextroamphetamine/ amphetamine
Black Box Warnings .
Abuse, Misuse, and Addiction
CNS stimulants have high potential for abuse and misuse, can lead to substance use disorder, incl. addiction; misuse and abuse can result in overdose and death, risk incr. w/ higher doses or unapproved admin. methods; assess risk for abuse, misuse, and addiction before prescribing and throughout tx; educate pts and families about risks and proper drug storage and disposal; monitor frequently for s/sx of abuse, misuse, and addiction during tx
Adult Dosing .
Dosage forms: ER CAP: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Special Note
- [formulation clarification]
- Info: not interchangeable w/ other dextroamphetamine/amphetamine products; do not substitute on a mg to mg basis; retitrate if switching between products
ADHD
- [12.5-50 mg PO qam]
- Start: 12.5-25 mg PO qam, may incr. by 12.5 mg/day no sooner than qwk; Max: 50 mg/day; Info: duration up to 16h; may open cap, but do not crush/chew contents
renal dosing
- [see below]
- eGFR 15-29: start 12.5 mg qd, max 25 mg/day; eGFR <15: avoid use
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: ER CAP: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Special Note
- [formulation clarification]
- Info: not interchangeable w/ other dextroamphetamine/amphetamine products; do not substitute on a mg to mg basis; retitrate if switching between products
ADHD
- [13-17 yo]
- Dose: 12.5-25 mg PO qam; Start: 12.5 mg PO qam, may incr. by 12.5 mg/day no sooner than qwk; Max: 25 mg/day; Info: duration up to 16h; may open cap, but do not crush/chew contents
renal dosing
- [see below]
- eGFR 15-29: max 12.5 mg/day; eGFR <15: avoid use
- HD/PD: not defined
hepatic dosing
- [not defined]